Pioneering Project for the Construction of a Biosimilar Drug Manufacturing Plant: Advancing the Biopharmaceutical Industry in Iran
Client: Shahr-e Salamat Pars Company
Role of ANIN Company: General Contractor
ANIN Engineering Company is proud to serve as the general contractor for the construction of a biosimilar drug manufacturing plant—an ambitious step toward the advancement of the high-tech biopharmaceutical industry in Iran. This knowledge-based sector, which focuses on the production of biological drugs derived from biological sources such as cells, genes, bacteria, and viruses, encompasses vital subfields including vaccine production, monoclonal antibodies, protein therapy, cell therapy, and gene therapy. Due to their complex structures and significant effectiveness, biological drugs play a crucial role in treating a wide range of chronic and complex diseases such as autoimmune disorders, various cancers, diabetes, chronic kidney disease, inflammatory bowel disease, and cystic fibrosis
The Islamic Republic of Iran, relying on its valuable pool of skilled professionals in genetics and medicine, possesses considerable technical know-how in producing cell-, gene-, and protein-based drugs. With strategic investment, Iran has the potential to rank among the top five countries in the world in producing and registering these types of medicines. Moreover, given the high global prices of these drugs and Iran’s competitive advantage in producing them at significantly lower costs, the development of this industry could ensure affordable access to essential medicines for domestic patients while also providing lucrative export opportunities for investors.
Recognizing the specialized potential within the country and after thoroughly assessing the domestic market and competitors, Shahr-e Salamat Pars Company has made a strategic decision to invest in establishing a biosimilar drug manufacturing facility in Kerman Province. Key objectives of this investment include addressing shortages of select medications in the domestic market, offering competitively priced products compared to imports, fostering the development of biological drug manufacturing as a pioneering national industry, and preventing the brain drain of experts and specialists in this field.
This facility will also serve as a strategic partner to the Kerman Comprehensive Cancer Hospital, playing a vital role in supplying part of the needed medications for cancer treatment. Additionally, it will provide a suitable platform for joint research in clinical drug effects and the development of new pharmaceuticals in collaboration with specialists from both institutions.
ANIN, leveraging its expertise and experience as the general contractor for this pioneering project, has been actively involved from the early planning and feasibility stages alongside a team of specialists in pharmaceutical production. The comprehensive services provided by ANIN include technical consulting, management and implementation planning, optimal site layout, preparation of conceptual and basic engineering designs, specialized cleanroom design, development of the factory’s master site plan, drafting technical specifications for equipment, securing funding, and offering project management and control services.
All design and planning stages have been carried out with the goal of achieving the internationally recognized EUGMP standard for the factory’s products and facilitating their export to global markets. To this end, the plant’s design has involved collaboration with an experienced foreign partner to ensure full compliance with the stringent EUGMP requirements.
The execution phase of the project will begin in the coming months following the completion of the detailed engineering design. The implementation, commissioning, and production launch are expected to take four years. ANIN, drawing on its engineering and operational capabilities, will be fully responsible for equipment procurement, implementation, and commissioning of this national project. The total area of the factory will be approximately 7,000 square meters, with over 5,000 square meters dedicated to advanced cleanroom facilities.
Committed to innovation and the development of knowledge-based industries in the country, ANIN will dedicate all its resources to successfully delivering this strategic project and helping elevate Iran’s position in the global biopharmaceutical sector. This project stands as a symbol of expert collaboration and national determination toward self-sufficiency and progress in the healthcare sector.
